TriangleChimeric Antigen Receptor T-Cell… (NCT06815029)
Chimeric Antigen Receptor T-Cell Therapy trial for Recurrent Glioblastoma (NCT06815029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Glioblastoma almost always returns after surgery, radiation, and chemotherapy; at recurrence, nothing reliably extends life.
The idea: deliver engineered immune cells straight into the brain, and delete the switch the tumor uses to shut them down.
City of Hope has treated glioblastoma with CAR T cells aimed at IL13Rα2, a marker on most of these tumors, infused through a small catheter into the brain. Glioblastoma pours out TGF-beta, which quiets immune cells. Here, the gene for the TGF-beta receptor is knocked out of the T cells first, so the tumor's brake no longer works on them. Doses are given weekly for four weeks, then more if tolerated.
Behnam Badie leads the trial in Duarte. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.